News stories about OvaScience (NASDAQ:OVAS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OvaScience earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.3427464066153 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Recros Medica Closes $9M Financing, Strengthens Board (finance.yahoo.com)
- Where OvaScience, Inc. (OVAS) stock is Headed Exactly? – The Stocks News (press release) (thestocksnews.com)
- Announces Corporate Update – Business Wire (press release) (businesswire.com)
- OvaScience, Inc., (NASDAQ: OVAS) – Beta Factor under Consideration – Stock Watch (stocksnewstimes.com)
- OvaScienceSM Announces Corporate Update (finance.yahoo.com)
Shares of OvaScience (OVAS) traded up $0.12 on Thursday, hitting $1.47. The stock had a trading volume of 2,071,600 shares, compared to its average volume of 1,686,350. The stock has a market cap of $48.38, a price-to-earnings ratio of -0.80 and a beta of 3.73. OvaScience has a 12-month low of $1.25 and a 12-month high of $2.05.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3125692/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-ovascience-ovas-share-price.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.